Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Financial Statements and Exhibits

Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.


EX-99.1 2 tv479292_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting –         ARRY-382 (CSF1R inhibitor) demonstrated initial signs of clinical activity when combined with KEYTRUDA® (anti-PD1 antibody) immunotherapy in patients with solid tumors – –         Array plans to expand ongoing Phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer –BOULDER,…
To view the full exhibit click here

About Array BioPharma Inc. (NASDAQ:ARRY)

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

An ad to help with our costs